Anavex Life Sciences Corp. filings document material events for a Nevada clinical-stage biopharmaceutical issuer with common stock listed on Nasdaq under AVXL. Recent Form 8-K disclosures cover financial results releases, securities registration details for its common stock, and corporate governance matters involving board appointments, executive employment arrangements, and leadership changes.
The filings also record regulatory disclosures tied to blarcamesine, including European Medicines Agency review matters for early Alzheimer’s disease and related press-release exhibits. These documents provide formal records of the company’s public-company reporting, clinical-development communications, governance actions, compensation arrangements, and capital-market security status.
Anavex Life Sciences Corp. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 by the prescribed May 11, 2026 due date. The delay is due to an independent Special Committee review after the termination of the prior CEO on April 30, 2026, and the appointment of an Interim CEO on May 4, 2026. The Company says the Special Committee and management are working to complete their review so the Form 10-Q can be filed.
Anavex Life Sciences Corp. reported a leadership change and a pending filing delay. A special committee of independent directors ended the employment of President and Chief Executive Officer Christopher Missling, PhD, for Cause under his employment agreement and asked him to resign from the Board.
The Board appointed Terrie Kellmeyer, PhD, a veteran drug development executive and former Senior Vice President of Clinical Development at Anavex, as Interim Chief Executive Officer effective May 4, 2026. Her compensation includes a $500,000 base salary, a target bonus equal to 30% of salary, a $150,000 signing bonus, and 200,000 stock options. The company also expects to file a Form 12b-25 to extend the deadline for its Form 10-Q for the quarter ended March 31, 2026.
ANAVEX LIFE SCIENCES CORP. director Axel Paeger filed an initial Form 3, which is a statement of beneficial ownership for company insiders. The filing shows no reported transactions, exercises, gifts, or restructurings and contains no derivative holdings or position details in this excerpt.
Anavex Life Sciences Corp ownership filing shows 0 shares beneficially owned by The Vanguard Group as amended. The filing explains an internal realignment within Vanguard that led certain subsidiaries to report separately in reliance on SEC Release No. 34-39538, and states Vanguard reports no beneficial ownership in this class.
Anavex Life Sciences Corp. reported that it has withdrawn its application for EU marketing authorization of its lead drug candidate blarcamesine as an add-on therapy for adults with early Alzheimer’s disease. The application had been under review by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
The withdrawal follows CHMP feedback indicating it would not be in a position to issue a positive opinion at this time. Anavex states it remains committed to the ongoing clinical development of blarcamesine and plans to gather additional data and conduct further analyses to address the points raised by the CHMP.
Anavex Life Sciences Corp. reported a governance update, announcing that its Board of Directors appointed Dr. Axel Paeger as a new director, effective February 23, 2026, to fill an existing vacancy. He will receive compensation consistent with other non-employee directors.
The Board determined that Dr. Paeger qualifies as an independent director under Securities Exchange Act rules and Nasdaq Capital Market listing standards. The company stated there are no special arrangements connected to his appointment and no related-party transactions requiring disclosure. A related press release dated February 23, 2026 was furnished as an exhibit.
Anavex Life Sciences Corp. reported a narrower net loss for the three months ended December 31, 2025 as it continued developing CNS drug candidates without generating product revenue. Net loss was $5.7 million, improved from $12.1 million a year earlier, driven by sharply lower research and development and general and administrative expenses.
Operating expenses fell to $6.8 million from $13.6 million, reflecting reduced clinical trial and share-based compensation costs. Other income of $1.1 million, mainly interest on cash, partly offset expenses. Anavex strengthened its balance sheet by raising $36.3 million through its 2025 at-the-market Sales Agreement, issuing about 6.0 million new shares.
Cash and cash equivalents rose to $131.7 million as of December 31, 2025, up from $102.6 million at September 30, 2025. Management states this working capital should fund operations for more than 12 months, even as the company expects continued negative operating cash flows while advancing programs in Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other CNS indications.
Anavex Life Sciences Corp. reported fiscal 2026 first quarter results and provided a business update focused on its lead oral blarcamesine program in early Alzheimer’s disease and other central nervous system disorders.
For the quarter ended December 31, 2025, Anavex recorded a net loss of $5.7 million, improved from a net loss of $12.1 million a year earlier. Operating expenses fell to $6.8 million from $13.6 million, reflecting lower general and administrative as well as research and development spending. Net loss per share narrowed to $0.06 from $0.14, on a higher weighted average share count of 89,029,458 basic and diluted shares, up from 84,805,974.
The company ended December 31, 2025 with $131.7 million in cash and cash equivalents, up from $102.6 million as of September 30, 2025, and total stockholders’ equity of $126.6 million, compared with $94.9 million at September 30, 2025. Management reiterated its focus on advancing blarcamesine and other pipeline candidates and hosted a webcast to discuss the quarter.
Anavex Life Sciences reported that President and CEO Christopher Missling had 125,000 stock options vest on January 6, 2026. These options have an exercise price of $8.58 per share and are shown as acquired at a price of $0, reflecting the vesting of an existing award rather than a market purchase. The options are part of a larger grant made on March 31, 2025 covering 500,000 shares, structured to vest in four equal performance-based tranches.
One milestone for this grant was achieving a Second Regulatory dialogue for blarcamesine. The filing states that the performance criteria for this milestone were met, causing this 125,000-share tranche to vest. Following the transaction, Missling directly holds 125,000 derivative securities (stock options), each representing one share of common stock, with an expiration date of March 31, 2035.
Anavex Life Sciences Corp. reported that its PFO & Treasurer, Sandra Boenisch, acquired a derivative security in the form of a stock option on January 6, 2026. The option covers 12,500 shares of common stock at an exercise price of $8.58 per share and is exercisable until March 31, 2035.
The 12,500-share tranche comes from an earlier option grant dated March 31, 2025 for 50,000 shares that vests in four equal performance-based tranches. One milestone was achieving a second regulatory dialogue for blarcamesine, and meeting this performance criterion triggered vesting of this 12,500-share portion, which Boenisch now holds directly.